Jun Chung, MD
Internal Medicine · Los Angeles, CANPI 1205190659
Payments from drug & device makers
Across 318 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- AbbVie$562
- Lilly USA, LLC$557
- Bayer$502
- Novo Nordisk$492
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 59 | $1,295 |
| AstraZeneca(2 entities) | 50 | $1,121 |
| AbbVie(2 entities) | 23 | $562 |
| Lilly USA, LLC | 25 | $557 |
| Bayer | 20 | $502 |
| Novo Nordisk | 26 | $492 |
| Boehringer Ingelheim | 19 | $491 |
| Ardelyx, Inc. | 12 | $379 |
| Merck | 17 | $283 |
| Phathom Pharmaceuticals, Inc. | 8 | $257 |
| Nestle Healthcare Nutrition Inc. | 9 | $196 |
| Aimmune Therapeutics, Inc. | 8 | $180 |
| Pfizer | 7 | $172 |
| Amarin Pharma, Inc. | 4 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $115 |
| Ironwood Pharmaceuticals, Inc | 5 | $105 |
| Novartis | 4 | $96 |
| Penumbra, Inc. | 1 | $96 |
| Gilead | 3 | $82 |
| GSK | 3 | $82 |
| Eisai Inc. | 2 | $56 |
| Insmed, Inc. | 2 | $50 |
| Shield Therapeutics Inc | 2 | $42 |
| Biogen | 1 | $27 |
| Exact Sciences | 1 | $20 |
| Abiomed | 1 | $15 |
How this compares
$7,393 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 109 | $187,968 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 207 | $147,020 |
| OzempicSemaglutide | 138 | $136,889 |
| CreonLipase/Protease/Amylase | 91 | $121,434 |
| KerendiaFinerenone | 157 | $115,684 |
| LinzessLinaclotide | 175 | $114,429 |
| VascepaIcosapent Ethyl | 225 | $99,727 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 102 | $88,206 |
| MounjaroTirzepatide | 62 | $82,773 |
| ProliaDenosumab | 42 | $72,380 |
| JardianceEmpagliflozin | 92 | $62,518 |
| RestasisCyclosporine | 85 | $53,716 |
| FarxigaDapagliflozin Propanediol | 74 | $50,463 |
| Xigduo XrDapaglifloz Propaned/Metformin | 46 | $43,417 |
| EliquisApixaban | 51 | $40,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jardiance, Tradjenta, Glyxambi | $491 | $353,107488 claims |
| AbbVieCreon, Linzess, Restasis | $562 | $289,579351 claims |
| Aimmune Therapeutics, Inc.Zenpep | $180 | $187,968109 claims |
| Novo NordiskOzempic, Rybelsus | $492 | $157,841152 claims |
| BayerKerendia | $502 | $115,684157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $557 | $107,54188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,121 | $82,017125 claims |
| AmgenProlia | $1,295 | $72,38042 claims |
| MerckJanumet Xr, Januvia | $283 | $54,02479 claims |
| PfizerEliquis | $172 | $40,80151 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $257 | $29,87547 claims |
| NovartisEntresto | $96 | $28,93931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.